Giuliani Michela, Gui Benedetta, Valentini Anna L, DI Giovanni Silvia E, Miccò Maura, Rodolfino Elena, Falcione Matteo, DE Waure Chiara, Palluzzi Eleonora, Salutari Vanda, Scambia Giovanni, Manfredi Riccardo
Diagnostic Imaging Area, Sacro Cuore Catholic University, Rome, Italy.
Diagnostic Imaging Area, Sacro Cuore Catholic University, Rome, Italy -
Minerva Ginecol. 2017 Dec;69(6):538-547. doi: 10.23736/S0026-4784.17.04062-X. Epub 2017 Jun 9.
There are no standard approaches for follow up in advanced ovarian cancer (AOC) patients; the aim of this study is to evaluate correlation between computed tomography (CT) and CA 125 levels to assess early detection of recurrence or progression disease (PD).
We included 76 patients with AOC, who had prior debulking surgery, starting first or second line of chemotherapy and underwent follow-up CT examinations. Evaluation of tumor response to treatment by imaging was assessed using RECIST 1.1. Site of relapse was classified as: abdomen, chest and neck (observed in the upper chest scans).
Change in CA 125 levels was calculated in respect previous evaluation at the end of treatment for each patient. The most suitable cut-offs could be identified in an increase in CA 125 levels >10.5% (sensitivity: 67.9%; specificity: 83.6%; LR+: 4.1; LR-: 0.4) in order to predict PD and in a change of -0.5% in order to exclude PD (sensitivity 83.0%; specificity: 69.6%; LR+: 2.7; LR-: 0.2). Site of relapse was abdomen (58.5%), abdomen and chest (33.9%), chest (3.8%), chest and neck (1.9%), and abdomen, chest and neck (1.9%).
Increase in CA 125 levels >10.5% could be sufficiently predictive of PD requiring CT examination. Change of -0.5% is sufficiently predictive of absence of PD. Increase <10.5% and >0.5% needs clinical correlation to establish correct timing and extension of CT examination. Attention must be played in reducing number and extent of CT examinations to reduce exposure dose.
晚期卵巢癌(AOC)患者尚无标准的随访方法;本研究旨在评估计算机断层扫描(CT)与CA 125水平之间的相关性,以评估复发或疾病进展(PD)的早期检测情况。
我们纳入了76例AOC患者,这些患者之前接受过肿瘤减灭术,开始一线或二线化疗,并接受了随访CT检查。使用RECIST 1.1评估通过影像学检查的肿瘤对治疗的反应。复发部位分类为:腹部、胸部和颈部(在上胸部扫描中观察到)。
针对每位患者在治疗结束时相对于之前的评估计算CA 125水平的变化。为了预测PD,CA 125水平升高>10.5%(敏感性:67.9%;特异性:83.6%;阳性似然比:4.1;阴性似然比:0.4)时可确定最合适的临界值,为了排除PD,变化为-0.5%时可确定最合适的临界值(敏感性83.0%;特异性:69.6%;阳性似然比:2.7;阴性似然比:0.2)。复发部位为腹部(58.5%)、腹部和胸部(33.9%)、胸部(3.8%)、胸部和颈部(1.9%)以及腹部、胸部和颈部(1.9%)。
CA 125水平升高>10.5%可充分预测需要进行CT检查的PD。变化为-0.5%可充分预测无PD。升高<10.5%且>0.5%需要临床关联以确定CT检查的正确时间和范围。必须注意减少CT检查的次数和范围以降低辐射剂量。